Status:

TERMINATED

Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression

Lead Sponsor:

Dartmouth-Hitchcock Medical Center

Conditions:

Treatment Resistant Depression

Depressive Disorder, Treatment-Resistant

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

The long term follow up of a pilot study in which the investigators proposed to test whether high frequency stimulation of the subcallosal cingulate (SCC) is a safe and efficacious antidepressant trea...

Detailed Description

The U.S. lifetime prevalence of major depressive disorder (MDD) is 17%. A number of treatments are available for depression including medications, psychotherapy and various somatic treatments. Unfortu...

Eligibility Criteria

Inclusion

  • Have received DBS for TRD
  • Ability to provide written informed consent
  • Willing to comply with all necessary study visits

Exclusion

  • Significant cerebrovascular risk factors or a previous stroke, documented major head trauma or neurodegenerative disorder.
  • Other currently active clinically significant Axis I psychiatric diagnosis including schizophrenia, panic disorder, obsessive-compulsive disorder, generalized anxiety disorder or post-traumatic stress disorder. Patients with severe Axis II personality disorders will also be excluded if the personality disorder is likely to interfere with cooperation and adherence to the study protocol.
  • Current psychotic symptoms.
  • Evidence of global cognitive impairment.
  • Substance abuse or dependence not in full sustained remission (i.e., not active for at least one year).
  • Active suicidal ideation with intent; suicide attempt within the last six months; more than three suicide attempts within the last two years.
  • Pregnancy or plan to become pregnant during the study period.
  • General contraindications for DBS surgery (cardiac pacemaker/defibrillator or other implanted devices).
  • Inability or unwillingness to comply with long-term follow-up.
  • History of intolerance to neural stimulation of any area of the body.
  • Participation in another drug, device or biologics trial within the preceding 30 days.
  • Conditions requiring repeated MRI scans.
  • Conditions requiring diathermy.
  • Conditions requiring anticoagulant medication.
  • Terminal illness associated with expected survival of \<12 months.

Key Trial Info

Start Date :

April 18 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2022

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03360942

Start Date

April 18 2016

End Date

September 30 2022

Last Update

December 12 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States, 03766